Login to Your Account



Clinic Roundup


Thursday, December 20, 2012

• Infectex, of Moscow, a biotech firm in the Maxwell Biotech Venture Fund's portfolio, said it enrolled the first patients in a Phase II/III trial of diamine compound SQ109 for multidrug-resistant tuberculosis. The two-year trial is expected to support regulatory approval in Russia and the Commonwealth of Independent States. It is designed to compare the effects of an optimized background drug regimen alone to an optimized background regimen plus SQ109. Infectex licensed rights to the drug from Sequella Inc., of Rockville, Md.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription